Leadership Overview
Simtra BioPharma Solutions has 4 executives leading key functions including strategy, information technology, operations, and financial management.
Focused on delivering high-quality sterile injectables, Simtra BioPharma Solutions maintains a commitment to precision and transparency while ensuring that every pharmaceutical product meets rigorous global standards for patient safety and manufacturing excellence.
Focused on delivering high-quality sterile injectables, Simtra BioPharma Solutions maintains a commitment to precision and transparency while ensuring that every pharmaceutical product meets rigorous global standards for patient safety and manufacturing excellence.
Leadership Roles at Simtra BioPharma Solutions
Franco Negron - Chief Executive Officer
Franco Negron, the Chief Executive Officer at Simtra BioPharma Solutions, directs the overarching strategic vision for the organization. Negron architects the long-term growth trajectory by aligning manufacturing capabilities with the evolving demands of the global sterile injectables market. By fostering a culture of precision and transparency, the Chief Executive Officer ensures that every facility maintains the highest quality standards required for complex pharmaceutical production. Negron collaborates with the board to secure capital investments that expand the company's service slate and product delivery options. This leadership role involves navigating the complexities of the pharmaceutical landscape to maintain a competitive edge in North American and international markets. Through rigorous oversight of operational performance, Franco Negron drives the company toward achieving consistent, on-time delivery for all clients. Ultimately, Negron secures the future of the organization by prioritizing patient needs and operational excellence in every strategic decision.
Tim Donovan - Chief Financial Officer
Tim Donovan, the Chief Financial Officer at Simtra BioPharma Solutions, manages the financial health and fiscal strategy of the organization. Donovan architects the budgetary framework that supports the company's extensive slate of services and manufacturing investments. By analyzing market trends and cost structures, the Chief Financial Officer ensures that the company maintains the capital necessary to meet evolving patient needs. Donovan collaborates with the executive team to allocate resources effectively, driving growth while maintaining the transparency required for pharmaceutical operations. This leadership role involves overseeing financial reporting, risk management, and long-term investment planning to secure the company's market position. Through the implementation of rigorous financial controls, Tim Donovan supports the organization's mission to deliver quality products on time and in full. Ultimately, Donovan ensures that the financial strategy aligns with the broader goals of the company, fostering sustainable success in the competitive pharmaceutical manufacturing sector.
Raymond Guidotti - Chief Operating Officer
Raymond Guidotti, the Chief Operating Officer at Simtra BioPharma Solutions, oversees the daily execution of sterile injectable manufacturing across all facilities. Guidotti directs the production teams to ensure that every batch meets the exact specifications required by pharmaceutical partners. By refining internal processes, the Chief Operating Officer maximizes efficiency and maintains the high standards necessary for complex product delivery. Guidotti manages the operational scale of the company, ensuring that resources align with the demand for high-quality sterile products. This leadership role involves constant monitoring of manufacturing performance to guarantee on-time delivery and full compliance with industry regulations. Through the optimization of production workflows, Raymond Guidotti drives the company's ability to handle diverse service requests with precision. Ultimately, Guidotti ensures that the operational backbone of the organization remains strong, allowing the company to fulfill its commitment to patient health and manufacturing excellence.
Mike Macrie - Chief Information Officer
Mike Macrie, the Chief Information Officer at Simtra BioPharma Solutions, manages the digital infrastructure supporting the company's sterile manufacturing processes. Macrie architects secure data systems that track every detail of the production cycle, ensuring full transparency for clients. By implementing advanced analytics, the Chief Information Officer optimizes supply chain visibility and enhances the precision of manufacturing workflows. Macrie coordinates with other C-suite leaders to integrate technology into the broader business model, facilitating seamless communication across global operations. This leadership role involves protecting sensitive pharmaceutical data while driving digital transformation initiatives that improve efficiency and compliance. Through the deployment of robust information systems, Mike Macrie supports the company's mission to deliver products right the first time. Ultimately, Macrie ensures that the technological foundation remains scalable and resilient, providing the necessary tools for the organization to meet complex patient requirements in a highly regulated industry.
Explore Leadership Teams in Manufacturing
Founded in 1974, Apotex is a proud Canadian, global pharmaceutical company that produces high-quality, affordable medicines (both generic and innovative pharmaceuticals) for patients around the world.
Company Leadership
DA
TM
Merz North America Inc is a company that operates in the Pharmaceuticals industry. It employs 1000to4999 people and has 500Mto1G of revenue. The company is headquartered in Raleigh, North Carolina.
Company Leadership
AS
JS
AS
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Company Leadership
CC
SR
United Therapeutics Corporation is a biotechnology company focused on the discovery, development, manufacturing, and commercialization of innovative therapies and advanced medical technologies for patients living with chronic, rare, and life-threatening diseases. The company is dedicated to addressing significant unmet medical needs by developing novel pharmaceutical treatments that improve patient outcomes and enhance quality of life
Company Leadership JR
JK
HH
Frequently Asked Questions Regarding Simtra BioPharma Solutions Top Executives and Leadership Team
